Skip to main content
Journal cover image

Oral platelet glycoprotein IIb/IIIa inhibition.

Publication ,  Journal Article
Newby, LK; McGuire, DK
Published in: Curr Cardiol Rep
September 2000

Platelet aggregation plays a central role in the pathogenesis of thrombosis and the acute coronary syndromes. When given intravenously, potent selective antagonists of fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor, the final common pathway for platelet aggregation, have been effective in the treatment of acute coronary syndromes. Their benefit ceases, however, with the end of the infusion. Aspirin reduces the incidence of secondary vascular events by 25% to 30% after an acute coronary syndrome, and clopidogrel provides modest improvement over aspirin. However, both are relatively weak antiplatelet agents that each block only one of many pathways to platelet activation and surface membrane expression of the competent GP IIb/IIIa receptor. With the success of the intravenous GP IIb/IIIa antagonists in the acute setting, recent interest has focused on the potential benefit of oral GP IIb/IIIa antagonists used long-term for secondary prevention. The oral agents tested in phase III studies thus far have not performed up to expectations, however. The following paper reviews these studies and the implications of their results.

Duke Scholars

Published In

Curr Cardiol Rep

DOI

ISSN

1523-3782

Publication Date

September 2000

Volume

2

Issue

5

Start / End Page

372 / 377

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Syndrome
  • Pyrrolidines
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Piperidines
  • Oximes
  • Myocardial Infarction
  • Humans
  • Clinical Trials, Phase III as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Newby, L. K., & McGuire, D. K. (2000). Oral platelet glycoprotein IIb/IIIa inhibition. Curr Cardiol Rep, 2(5), 372–377. https://doi.org/10.1007/s11886-000-0049-7
Newby, L. K., and D. K. McGuire. “Oral platelet glycoprotein IIb/IIIa inhibition.Curr Cardiol Rep 2, no. 5 (September 2000): 372–77. https://doi.org/10.1007/s11886-000-0049-7.
Newby LK, McGuire DK. Oral platelet glycoprotein IIb/IIIa inhibition. Curr Cardiol Rep. 2000 Sep;2(5):372–7.
Newby, L. K., and D. K. McGuire. “Oral platelet glycoprotein IIb/IIIa inhibition.Curr Cardiol Rep, vol. 2, no. 5, Sept. 2000, pp. 372–77. Pubmed, doi:10.1007/s11886-000-0049-7.
Newby LK, McGuire DK. Oral platelet glycoprotein IIb/IIIa inhibition. Curr Cardiol Rep. 2000 Sep;2(5):372–377.
Journal cover image

Published In

Curr Cardiol Rep

DOI

ISSN

1523-3782

Publication Date

September 2000

Volume

2

Issue

5

Start / End Page

372 / 377

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Syndrome
  • Pyrrolidines
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Piperidines
  • Oximes
  • Myocardial Infarction
  • Humans
  • Clinical Trials, Phase III as Topic